JR-141
Phase 2/3Completed 0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Aug 1, 2018 → Feb 20, 2020
NCT ID
NCT03568175About JR-141
JR-141 is a phase 2/3 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is completed. This product is registered under clinical trial identifier NCT03568175. Target conditions include Mucopolysaccharidosis II.
What happened to similar drugs?
5 of 15 similar drugs in Mucopolysaccharidosis II were approved
Approved (5) Terminated (1) Active (10)
Hype Score Breakdown
Clinical
15
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05594992 | Phase 3 | Recruiting |
| NCT04348136 | Phase 2/3 | Active |
| NCT03708965 | Phase 2 | Active |
| NCT03568175 | Phase 2/3 | Completed |
| NCT03128593 | Phase 1/2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis II